‘The beginning of the end’
The recent announcement of donanemab from US pharmaceutical company Eli Lilly brings new hope for the future of dementia treatments.
This potential new drug for early-stage Alzheimer’s disease could help people live better with dementia, for longer. After lecanemab in 2022, this is the second drug shown to slow the progression of Alzheimer’s disease, bringing us to a tipping point in dementia research.
Donanemab has been developed from the amyloid hypothesis – first posited by Professor Sir John Hardy in a research project funded by Alzheimer’s Society supporters over 35 years ago.
Your support continues to fund the best dementia research that improves diagnosis, unlocking access to life-changing treatments when they are available. Donate today and read more about donanemab on our blog.